<DOC>
	<DOCNO>NCT00125411</DOCNO>
	<brief_summary>This single center , open-label , non-randomized , Phase I dose find study investigational , oral cytotoxic drug , satraplatin ( JM-216 ) , combination docetaxel patient advance solid tumor curative therapy available . Please refer Eligibility Criteria key inclusion exclusion criterion . PURPOSE : The purpose trial determine tolerable dose schedule combination satraplatin docetaxel give patient advance solid tumor . WHAT IS SATRAPLATIN : Satraplatin oral , investigational anticancer drug member platinum-based class chemotherapy drug . Platinum-based drug clinically prove one effective class anticancer therapy . Unlike currently market platinum-based drug , satraplatin give orally .</brief_summary>
	<brief_title>Study Satraplatin ( JM-216 ) Combination With Docetaxel</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Satraplatin</mesh_term>
	<criteria>Histologically confirm malignancy metastatic unresectable standard curative palliative chemotherapy measure exist longer effective Life expectancy least 3 month Measurable evaluable disease ECOG performance status &lt; = 2 Willingness ability give inform consent Women pregnant breastfeed Other chemotherapy treatment le 4 week prior enrollment Treatment docetaxel platinum agent le 3 month prior enrollment Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>satraplatin</keyword>
	<keyword>docetaxel</keyword>
	<keyword>cancer</keyword>
	<keyword>Phase I</keyword>
	<keyword>advanced solid tumor</keyword>
</DOC>